(VIANEWS) – SELECTIRENTE (SELER.PA), SANOFI (SAN.PA), ASR NEDERLAND (ASRNL.AS) are the highest payout ratio stocks on this list.
We have congregated information about stocks with the highest payout ratio as yet. The payout ratio in itself isn’t a guarantee of good investment but it’s an indicator of whether dividends are being paid and how the company chooses to issue them.
When researching a potential investment, the dividend payout ratio is a good statistic to know so here are a few stocks with an above 30% percent payout ratio.
1. SELECTIRENTE (SELER.PA)
64.75% Payout Ratio
Selectirente is a public real estate fund managed by Sofidy. It invests in city center and suburb commercial properties, which should be located close to shopping malls. It primarily acquires properties in France. As of March 29, 2019, Selectirente operates as a subsidiary of Tikehau Capital.
Earnings Per Share
As for profitability, SELECTIRENTE has a trailing twelve months EPS of €2.62.
PE Ratio
SELECTIRENTE has a trailing twelve months price to earnings ratio of 38.21. Meaning, the purchaser of the share is investing €38.21 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.59%.
Moving Average
SELECTIRENTE’s value is under its 50-day moving average of €100.05 and above its 200-day moving average of €96.79.
Revenue Growth
Year-on-year quarterly revenue growth grew by 25.8%, now sitting on 32.7M for the twelve trailing months.
Volume
Today’s last reported volume for SELECTIRENTE is 10 which is 11.11% above its average volume of 9.
2. SANOFI (SAN.PA)
50% Payout Ratio
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for Parkinson's disease; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Amunix Pharmaceuticals, Inc for T-cell engagers and cytokine therapies. It also enters in a strategic collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, SANOFI has a trailing twelve months EPS of €9.68.
PE Ratio
SANOFI has a trailing twelve months price to earnings ratio of 13.61. Meaning, the purchaser of the share is investing €13.61 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.77%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 10%, now sitting on 45.39B for the twelve trailing months.
Sales Growth
SANOFI’s sales growth is 11.4% for the ongoing quarter and 3.5% for the next.
Volume
Today’s last reported volume for SANOFI is 553227 which is 65.9% below its average volume of 1622750.
3. ASR NEDERLAND (ASRNL.AS)
42.31% Payout Ratio
ASR Nederland N.V. provides insurance, pensions, and mortgages products for consumers, self-employed persons, and companies. It operates through five segments: Non-Life, Life, Asset Management, Distribution and Services, and Holding and Other. The company distributes insurance contracts; provides financial intermediary services; and develops real estate properties. It operates as an asset manager for third parties. ASR Nederland N.V. offers its products under the De Amersfoortse, Loyalis, Ditzo, Europeesche Verzekeringen, and Ardanta brand names. The company was formerly known as Fortis Verzekeringen Nederland N.V. and changed its name to ASR Nederland N.V. in October 2008. ASR Nederland N.V. was founded in 1720 and is headquartered in Utrecht, the Netherlands.
Earnings Per Share
As for profitability, ASR NEDERLAND has a trailing twelve months EPS of €5.07.
PE Ratio
ASR NEDERLAND has a trailing twelve months price to earnings ratio of 7.21. Meaning, the purchaser of the share is investing €7.21 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.26%.
Moving Average
ASR NEDERLAND’s value is way below its 50-day moving average of €42.88 and way under its 200-day moving average of €41.83.
4. EQUASENS (EQS.PA)
37.7% Payout Ratio
Equasens Société anonyme provides various IT solutions for the healthcare sector in Europe. It offers LGPI global services and OffiCentral solutions for managing pharmacies and their networks; OffiMSS, OffiSecure, OffiProtect, OffiPass, OffiSeen, OffiCash, Offizzy, and OffiLocker solutions for pharmacists' business processes; and solutions for energizing the customer relationship with pharmacists comprising OffiTag, OffiTouch, OffiMédia, OffiConnect, automation systems, and customer loyalty programs. The company also provides My Pilot, an analytics and management tool; OffiLearning, an e-learning tool; and solutions for patient support and advice, such as compliance monitoring software, Multimeds, Automeds, and OffiTéléconsult, as well as pharmaceutical record and shared medical record services. In addition, it offers a ULTIMATE, a system combining optimized pharmacy management and improved patient support; FARMACLICK, a protocol for communications between pharmacies and wholesalers-distributors; DIFARM, a solution for wholesalers-distributors; PHARE, a retail management tool; SOPHIA, a pharmacy management application; OffiMédia POS display; eNephro to enhance the care of chronic renal failure patients; and TPE Pilot, a web-based application that simplifies the management and sharing of patient education programs. Further, the company provides NOVIACARE; CARELIB Domicile; CARELIB EHPAD; KAPELSE solutions; TITAN solutions; ANTHADINE software and MOBISOINS mobile tool; MICROSOINS, an in-home nursing care solution; and LOGICLIC. Additionally, it offers AXIGATE solutions to manage the entire patient care pathway; CHORUS platform; medical telesecretarial services for healthcare professionals; and equipment lease financing solutions. The company was incorporated in 1996 and is based in Villers-les-Nancy, France. Equasens Société anonyme is a subsidiary of Marque Verte Sante.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 28.59%.
Sales Growth
EQUASENS’s sales growth is 11.3% for the present quarter and 11.3% for the next.
Moving Average
EQUASENS’s worth is under its 50-day moving average of €77.40 and below its 200-day moving average of €76.13.
